January 8, 2026 — Leads & Copy — GeneDx, a leader in genomic insights for improved health outcomes, has partnered with Komodo Health, an AI-powered healthcare intelligence leader, to enhance rare disease research.
The collaboration integrates GeneDx’s Infinity™ with Komodo’s Healthcare Map® to create a comprehensive dataset for rare diseases, providing insights into diagnosis, management, and treatment across the patient journey.
GeneDx Infinity, the world’s largest rare disease genomic dataset, includes over 2.5 million genetic tests and 7 million phenotypic data points. More than half of the individuals represented are of non-European ancestry, promoting diversity in rare disease data.
Komodo’s Healthcare Map offers insights into the healthcare journeys of over 330 million de-identified patients. By combining genomic and phenotypic data from GeneDx with Komodo’s Healthcare Map, including the Komodo Research Dataset, researchers can gain insights into care pathways, outcomes, and unmet needs.
Lisa Gurry, Chief Business Officer at GeneDx, said the partnership will create the most comprehensive longitudinal view of rare diseases to date, accelerating Health Economics and Outcomes Research (HEOR), advancing biopharma innovation, and speeding up access to effective therapies for patients.
Together, GeneDx and Komodo aim to enable biopharma companies and researchers to move faster across the innovation life cycle, from discovery to outcomes, while maintaining privacy and ethical data use. All data integrations and analysis will use de-identified, privacy-preserving methods to ensure regulatory compliance and protect patient confidentiality.
Miles Ennis, Chief Operating Officer at Komodo Health, said the partnership underscores their commitment to setting a new standard for rare disease research by delivering actionable intelligence to identify patients earlier, close gaps in care, and drive impact at scale.
The combined dataset will support various use cases, including RWE generation for HEOR, research and development, clinical trials, market access, and AI and advanced analytics.
GeneDx Infinity continues to grow, generating 30% more exome and genome data in 2025 than in the previous 24 years combined. It includes nearly one million exomes and genomes sequenced, one million uniquely classified variants, nearly 5,000 validated gene-disease associations, and more than 5,600 emerging associations.
The partnership aims to expand possibilities in rare disease research and accelerate the path from data to life-changing outcomes for patients, setting a new benchmark for scale, depth, and impact in rare disease intelligence.
About GeneDx
GeneDx (Nasdaq: WGS) is a global leader in rare disease diagnosis, aiming to empower everyone to live healthier through genomics. GeneDx combines clinical expertise, advanced technology, and GeneDx Infinity™, the world’s largest rare disease genomic dataset, to power its ExomeDx™ and GenomeDx™ tests. GeneDx Infinity also fuels discovery for biopharma with AI-driven genomic intelligence.
About Komodo Health
Komodo Health aims to reduce the global burden of disease by building foundational AI for how Life Sciences and healthcare organizations discover, develop, and deliver life-saving therapies. The company’s healthcare-native AI platform Marmot, powered by its Healthcare Map, accelerates critical healthcare decisions across the product life cycle.
Contact:
Investor Relations
investors@genedx.com
Media Relations
press@genedx.com
Source: GeneDx
